Open access
Risk of Inflammatory Bowel Disease After Anti-CD20 Treatment in Multiple Sclerosis
Medicine
Abstract
This cohort study investigates if anti-CD20 treatment is associated with an increase in the risk of inflammatory bowel disease in individuals with multiple sclerosis (MS).